| Literature DB >> 24699001 |
Mizuho Aoki-Nakano1, Yoshiya Furusawa2, Akiko Uzawa1, Yoshitaka Matsumoto1, Ryoichi Hirayama1, Chizuru Tsuruoka1, Takashi Ogino3, Teiji Nishio3, Kazufumi Kagawa4, Masao Murakami4, Go Kagiya5, Kyo Kume5, Masanori Hatashita5, Shigekazu Fukuda6, Kazutaka Yamamoto7, Hiroshi Fuji8, Shigeyuki Murayama8, Masaharu Hata9, Takeji Sakae9, Hideki Matsumoto10.
Abstract
We investigated the relative biological effectiveness (RBE) of therapeutic proton beams at six proton facilities in Japan with respect to cell lethality of HSG cells. The RBE of treatments could be determined from experimental data. For this purpose, we used a cell survival assay to compare the cell-killing efficiency of proton beams. Among the five linear accelerator (LINAC) X-ray machines at 4 or 6 MeV that were used as reference beams, there was only a small variation (coefficient of variation CV = 3.1% at D10) in biological effectiveness. The averaged value of D10 for the proton beams at the middle position of the spread-out Bragg peak (SOBP) was 4.98. These values showed good agreement, with a CV of 4.3% among the facilities. Thus, the average RBE10 (RBE at the D10 level) at the middle position of the SOBP beam for six facilities in Japan was 1.05 with a CV of 2.8%.Entities:
Keywords: cell survival; proton therapy; relative biological effectiveness; spread-out Bragg-peak
Mesh:
Year: 2014 PMID: 24699001 PMCID: PMC4099996 DOI: 10.1093/jrr/rru003
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Summary of facilities and D10, D37, SF2 and RBEs
| Facility | A | B | C | D | E | F | Average | CV (%) |
|---|---|---|---|---|---|---|---|---|
| Year of experiment | 2000 | 2001 | 2002 | 2002 | 2002 | 2011 | ||
| Proton energy (MeV) | 190 | 180 | 190 | 190 | 200 | 235 | ||
| Dose rate (Gy/min) | ∼1.5 | ∼2.0 | 1.6–2.7 | 1.0–1.5 | 0.9–1.3 | ∼3.0 | ||
| Reference X-ray (MeV) | 4 | 4 | 6 | 4 | 4 | |||
| Proton D10 (Gy) | 5.1 | 4.97 | 4.91 | 5.32 | 4.92 | 4.68 | 4.98 | 4.3 |
| Proton D37 (Gy) | 2.87 | 2.44 | 2.72 | 3.09 | 2.9 | 2.44 | 2.74 | 9.5 |
| Proton SF2 | 0.655 | 0.557 | 0.687 | 0.707 | 0.628 | 0.458 | 0.615 | 15.1 |
| X-ray D10 (Gy) | 5.25 | 5.29 | 5 | 5.42 | b | 5.1 | 5.21 | 3.1 |
| X-ray D37 (Gy) | 2.88 | 2.97 | 2.88 | 3.13 | b | 2.87 | 2.95 | 3.8 |
| X-ray SF2 | 0.655 | 0.655 | 0.621 | 0.704 | 0.541 | 0.635 | 9.5 | |
| RBE10a | 1.03 ± 0.06 | 1.06 ± 0.05 | 1.02 ± 0.06 | 1.02 ± 0.05 | 1.07 ± 0.06 | 1.09 ± 0.03 | 1.05 | 2.8 |
| RBE37a | 1.00 ± 0.05 | 1.22 ± 0.14 | 1.06 ± 0.05 | 1.01 ± 0.06 | 1.02 ± 0.07 | 1.18 ± 0.10 | 1.08 | 8.6 |
The width of the SOBP was 60 mm for all facilities. aRBE at 10% and 37% survival levels; values are the average and SD for each facility. bThere was no High-energy LINAC X-ray machine available at facility E. Averaged values from facilities A–D were used in the RBE calculation.
Fig. 1.Survival curves of HSG cells obtained A) from LINAC high-energy X-ray machines at five different therapy facilities located at the corresponding proton facility, and B) at the middle position of 6-cm SOBP beams at six different proton therapy facilities. The red, blue, green, black, brown and broken lines correspond to each facility A to F, respectively. The symbols and bars are the mean and the standard deviation, respectively, obtained from at least three independent experiments.